Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
  • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

• tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors
• the invention relates to the use of tryptophan derivatives for the specific cytostatic treatment of serotonin-producing tumors, such as carcinoids and others. Areas of application of the invention are medicine and the pharmaceutical industry.
• Carcinoids are unusual neuroendocrine tumors, which predominantly occur in the gastrointestinal tract and arise from the transformation of chromaffin cells in the Lieberkühn crypts (Neary et al., Dis. Colon Rectum 40: 349-362, 1997), but also occur in the lungs and in Pancreas. Carcinoids can only be removed surgically, since conventional adjuvant therapy, especially advanced serotonin-producing tumors, is unsatisfactory because these tumor cells are resistant to conventional cytostatics (Neary et al, Dis. Colon Rectum 40: 349-362, 1997; Litvak et al, Surgery 124: 1071-1076, 1998).
• serotonin-producing lung tumor the so-called small cell lung carcinoma, and for mastocytomas.
• serotonin apparently acts as an autocrine growth hormone, which is why it is desirable on the one hand to reduce the serotonin synthesis, and on the other hand to act on the tumor cells with specific toxins.
• the object of the invention is therefore to search for and provide substances which enable the treatment of serotonin-producing tumors. These substances are said to act on the one hand as specific cytostatics, but at the same time they are also intended to reduce the serotonin synthesis as such.
• hydroxylated tryptophan derivatives which are poisoned in particular in the above-mentioned malignant cells by the body's own enzymes tryptophan hydroxylase (TPH) and aromatic amino acid decarboxylase (AAAD) to reduce and / or inhibit the synthesis of serotonin used in tumor cells, whereby these cells are specifically killed.
• TPH tryptophan hydroxylase
• AAAD aromatic amino acid decarboxylase
• the tryptophan derivatives 7-HTP, 6-HTP or 4-HTP, and derivatives which are further substituted on the aromatic system of tryptophan and which are converted into specific toxins are preferably used.
• the toxins 5,7-DHT and 5,6-DHT e.g. have long been used in research to examine lesions of tissues in which the serotonin transporter is expressed. This leads to the cytotoxic effect of a large number of cells expressing serotonin transporters that are not identical to cells producing serotonin. In addition, these substances are difficult to handle because of their high sensitivity to oxidation.
• tryptophan hydroxylase is inhibited competitively with hydroxylated tryptophan derivatives since they compete with the actual substrate, tryptophan. This prevents the autocrine growth promotion of the serotonin on these malignant cells.
• tryptophan derivatives preferably hydroxylated derivatives such as e.g. the 7-HTP, 6-HTP or 4-HTP an effective cytostatic agent for the treatment of serotonin-producing tumors, such as carcinoids.
• the tryptophan derivatives specifically inhibit tryptophan hydroxylase, thereby protecting against the autocrine growth requirement of serotonin on the escuonin-producing tumors.
• Primary tumors can therefore be treated and metastases destroyed cytostatically.
• the cytostatic agents according to the invention for chemotherapy of malignant diseases based on serotonin-producing tumors are characterized in that they contain hydroxylated tryptophan derivatives with conventional carriers and auxiliaries, preferably the derivatives 7-HTP, 6-HTP and 4-HTP.
• they are used for the therapy of neuroendocrine tumors, which predominantly occur in the gastrotestinal tract, in the lungs and in the pancreas, and in certain other serotonin-producing lung tumors, especially the small cell lung carcinoma and mastocytomas.
• the agents are preferably in formulations for parenteral and / or oral administration or, if appropriate, also in the form of liposomal complexes.
• FIG. 1 Reaction scheme for the enzymatic conversion of 7-hydroxy-tryptophan (7-HTP) to 5,7-dihydroxy-tryptamine (5,7-DHT).
• the rate-determining first step is mediated by the enzyme tryptophan hydroxylase (TPH), followed by rapid decarboxylation by aromatic amino acid decarboxylase (AAAD).
• TPH tryptophan hydroxylase
• AAAD aromatic amino acid decarboxylase

Landscapes

• Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Epidemiology (AREA)
• Oncology (AREA)
• Pulmonology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=7677818

Family Applications (1)

Country Status (7)

Cited By (1)

Families Citing this family (3)

Family Cites Families (6)

• 2001
  • 2001-03-15 DE DE10112882A patent/DE10112882A1/de not_active Withdrawn
• 2002
  • 2002-03-15 JP JP2002573016A patent/JP2004519500A/ja not_active Withdrawn
  • 2002-03-15 EP EP02732330A patent/EP1368027B1/de not_active Expired - Lifetime
  • 2002-03-15 US US10/471,776 patent/US20040097576A1/en not_active Abandoned
  • 2002-03-15 DE DE50200757T patent/DE50200757D1/de not_active Expired - Fee Related
  • 2002-03-15 ES ES02732330T patent/ES2225789T3/es not_active Expired - Lifetime
  • 2002-03-15 AT AT02732330T patent/ATE272400T1/de not_active IP Right Cessation
  • 2002-03-15 WO PCT/DE2002/000959 patent/WO2002074309A2/de not_active Ceased
• 2007
  • 2007-08-30 US US11/847,970 patent/US20070299128A1/en not_active Abandoned

Also Published As

Similar Documents

Legal Events